Who benefits from the blood pressure-lowering effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease? - Obese or non-obese?

Hypertens Res. 2024 Mar;47(3):681-682. doi: 10.1038/s41440-023-01543-0. Epub 2023 Dec 15.

Author

Kazuki Shiina¹

Affiliation

¹ Department of Cardiology, Tokyo Medical University, Tokyo City, Japan. shiina@tokyo-med.ac.jp.

PMID: 38102215
DOI: 10.1038/s41440-023-01543-0

No abstract available

Keywords: Blood pressure-lowering effects; Chronic kidney disease; Obesity; SGLT2 inhibitors; Type 2 diabetes mellitus.

Publication types

Editorial
Comment

MeSH terms

Blood Pressure / physiology
Body Mass Index
Diabetes Mellitus, Type 2* / blood
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose / pharmacology
Humans
Hypoglycemic Agents / pharmacology
Obesity / complications
Obesity / drug therapy
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents
Glucose
Sodium